A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Phase 1 Terminated 15 enrolled Georgetown University Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.

Timeline

Start: 2014-05
Primary completion: 2016-12
Completion: 2016-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	—
Subject	Nilotinib	Small molecule	200 mg	—
Subject	Nilotinib	Small molecule	300 mg	—

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Summary

Timeline

Drugs

Indications